Skip to main content

Table 2 Clinical response and symptomatic remission outcomes in the short-term study by treatment group (efficacy population, n=414)

From: Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder

  LDX Placebo
  30 mg/d (n=115) 50 mg/d (n=117) 70 mg/d (n=120) All Doses (n=352) (n=62)
Clinical response, n (%) 77 (67.0) 83 (70.9) 84 (70.0) 244 (69.3b) 23 (37.1b)
Time to median clinical response, a d (95% CI) 16.0 (15.0, 22.0) 15.0 (15.0, 21.0) 15.0 (13.0, 18.0) 15.0 (15.0, 17.0) 31.0 (29.0, NA)
Symptomatic remission, n (%) 51 (44.3) 47 (40.2) 62 (51.7) 160 (45.5c) 10 (16.1c)
Time to median symptomatic remission, d (95% CI) 31.0 (23.0, 37.0) NA 29.0 (21.0, 31.0) 31.0 (28.0, 37.0)  
  1. aRelative to baseline time to median clinical response in the 4-week trial.
  2. bSee Figure 1.
  3. cSee Figure 2.
  4. Abbreviations: d day, CI confidence interval, LDX lisdexamfetamine dimesylate, NA not assessed.